Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

'Treat-to-target': a call for earlier targeted intervention in asthma.

Couillard S. et al, (2025), J Allergy Clin Immunol Pract

Tezepelumab can Restore Normal Lung Function in Patients with Severe, Uncontrolled Asthma: Pooled Results from the PATHWAY and NAVIGATOR Studies.

Pavord ID. et al, (2025), Pulmonary therapy

Cough Reflex Hypersensitivity: A Common and Important Treatable Trait.

Pavord ID. and Gibson PG., (2025), J Allergy Clin Immunol Pract, 13, 499 - 500

Inflammatory and clinical prognostic factors for asthma attacks: a patient-level meta-analysis of control arms of 22 randomised trials

Meulmeester FL. et al, (2025), The Lancet Respiratory Medicine

Treatable Traits in Patients with Obstructive Lung Diseases in a Well-Established Asthma/COPD Service for Primary Care.

Dijk L. et al, (2025), International journal of chronic obstructive pulmonary disease, 20, 1189 - 1201

Effects of azithromycin in severe eosinophilic asthma with concomitant monoclonal antibody treatment.

Lavoie G. et al, (2024), Thorax

Stability of Fractional Exhaled Nitric Oxide and its Relationship with Exacerbation in Patients Aged 6 Years or Older with Uncontrolled, Moderate-to-Severe Asthma

Busse WW. et al, (2024), CHEST

Effects of azithromycin in severe eosinophilic asthma with concomitant monoclonal antibody treatment

Lavoie G. et al, (2024), Thorax

Biologics in Asthma: Role of Biomarkers.

Lavoie G. and Pavord ID., (2024), Immunol Allergy Clin North Am, 44, 709 - 723

Dupilumab Induces Long-Term On-Treatment Clinical Remission in Patients With Type 2 Asthma.

Pavord ID. et al, (2024), J Allergy Clin Immunol Pract

Navigating uncertainty: asthma biologics during pregnancy.

Howell I. et al, (2024), Lancet Respir Med

New thinking and a new direction in bronchiectasis.

Pavord ID., (2024), Lancet Respir Med

IL-5 antagonism reverses priming and activation of eosinophils in severe eosinophilic asthma.

Luo J. et al, (2024), Mucosal Immunol, 17, 524 - 536

Airway proteomics reveals broad residual anti-inflammatory effects of prednisolone in mepolizumab-treated asthma

HINKS T., (2024), Journal of Allergy and Clinical Immunology

Urinary eicosanoids in T2-low severe asthma: relationship with symptoms and exacerbation profile

M E. et al, (2024)

A Simulation Study of the Effect of Clinical Characteristics and Treatment Choice on Reliever Medication Use, Symptom Control and Exacerbation Risk in Moderate-Severe Asthma.

Garcia G. et al, (2024), Adv Ther

Species-level, metagenomic and proteomic analysis of microbe-immune interactions in severe asthma

JABEEN M. et al, (2024), Allergy

CHARACTERIZATION OF MODERATE AND SEVERE ASTHMA EXACERBATIONS IN THE CAPTAIN STUDY.

Oppenheimer J. et al, (2024), J Allergy Clin Immunol Pract

Blood eosinophils and lung function loss: from passive prediction to active prevention?

Ramakrishnan S. et al, (2024), Eur Respir J, 63

The Rebirth of Lebrikizumab for Airway Disease.

Pavord ID., (2024), J Allergy Clin Immunol Pract, 12, 1225 - 1227

Load More

1
2
3
4
5
6
7

Include forthcoming?